by Paul Krzyzanowski | Jul 17, 2012
Faced with patent shortages to replace flagship products, Big Pharma is increasing investments in smaller biotech companies to capture innovations early. Most new companies wither and die if they run out of initial funds before they’re profitable. In biotech,...
by Paul Krzyzanowski | May 16, 2012
Commercialization plenary summary: part 4 of 4 The last speaker of the commercialization plenary at the Till and McCulloch Meetings earlier this month was Dr. Stephen Minger from GE Healthcare, who shared GE’s perspective regarding the therapeutic and research...
by Paul Krzyzanowski | May 4, 2012
Commercialization plenary summary: part 3 of 4 On day two (May 1) of the Till and McCulloch Meetings, Dr. Emily Culme-Seymour from the London Regenerative Medicine Network introduced work that leverages previous clinical trial information to support future cell...
by Paul Krzyzanowski | May 1, 2012
Commercialization plenary summary, part 2 of 4 One of the most dynamic speakers of the conference thus far was Greg Bonfiglio of Proteus Venture Partners. A well-known VC speaker in this area, Bonfiglio shared his perspectives of how the commercialization of...
by Paul Krzyzanowski | May 1, 2012
Commercialization plenary summary, part 1 of 4 Till and McCulloch Meeting (#TMM2012) attendees in Montreal had the opportunity to hear from four speakers involved in commercializing discoveries in regenerative medicine, from the perspectives of not-for-profit,...
by Paul Krzyzanowski | Mar 27, 2012
Without a doubt, scientific research has the potential to discover new knowledge that can be used to improve human life. New tools and new ways of doing things are constantly being developed or invented, but arguably need to be commercialized before their benefits...
Comments